China Digest: Property agency Julive nets $62m; Style3D closes $31m
March 11, 2021
Chinese online-to-offline (O2O) real estate agency Julive has raised 400 million yuan ($61.6 million) in a Series C+ round, while Style3D, which provides 3D digital modeling software for the apparel design industry, has secured 200 million yuan ($30.8 million) in a Series Pre-B round.
Tencent, Oceanpine lead $62m round in Julive
Chinese O2O real estate agency Julive announced on Thursday the completion of a Series C+ funding round at $62 million led by Tencent and growth equity investment firm Oceanpine Capital.
Sequoia Capital China; Source Code Capital, the Beijing-based investor behind TikTok owner ByteDance and food delivery giant Meituan; and global venture capital (VC) firm Eight Roads participated in the deal.
Regor Therapeutics Announces Completion of $90 Million Series B Financing
News provided by
Share this article
Share this article
SHANGHAI, Feb. 18, 2021 /PRNewswire/ Regor Therapeutics, a clinical stage biotechnology company dedicated to the discovery of innovative medicines to treat cancer, immune disorders and metabolic diseases, announces the successful completion of $90 million Series B financing.
Founded in July of 2018 by a group of veteran drug hunters with extensive research and executive leadership experiences at top multinational pharmaceutical companies, Regor aims to establish world-class innovation capabilities and is committed to delivering clinically differentiated, best- and first-in-class drugs to serve patients globally. By leveraging CARD, Computer Accelerated Rational Discovery, a proprietary enabling technology platform, the team has successfully advanced numerous discovery programs in a dramatically accelerated fashion, including from ideas to a clinica
Regor Therapeutics Announces Completion of $90 Million Series B Financing apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Chinese biotech firm Binhui secures $93m Series C led by Temasek’s Vertex Ventures, others
Photo: Pixabay
February 10, 2021
Gene-focused biotechnology player Wuhan Binhui Biotech on Wednesday announced the completion of a 600 million yuan ($93 million) Series C round funding jointly led by healthcare-focussed Share Capital, Temasek’s Vertex Ventures China, Qianhai FOF, and CICC Capital’s sub-fund.
Returning investor Beijing Lapam Capital Management re-upped in the latest round, Binhui Biotech said in a WeChat post. Lapam had partnered Fortune Capital to seed 26.5 million yuan ($4 million) in Binhui in 2017. In 2018, Lapam exclusively poured 20 million yuan ($3 million) into the company.
With the latest Series C proceeds, Binhui expects to fund clinical trials, pipelines, and R&D platform advancements.